Arcadia Biosciences, Inc.
RKDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5 | $4 | $7 | $7 |
| % Growth | 13.3% | -40% | 9.4% | – |
| Cost of Goods Sold | $3 | $2 | $6 | $9 |
| Gross Profit | $2 | $2 | $1 | -$2 |
| % Margin | 41.3% | 51.2% | 17.8% | -28.4% |
| R&D Expenses | $0 | $0 | $2 | $4 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $10 | $8 | $15 | $23 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$4 | $0 | -$1 | $7 |
| Operating Expenses | $6 | $8 | $15 | $34 |
| Operating Income | -$4 | -$6 | -$14 | -$36 |
| % Margin | -72.3% | -137% | -188.8% | -524% |
| Other Income/Exp. Net | -$1 | $1 | $3 | $19 |
| Pre-Tax Income | -$4 | -$5 | -$11 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$14 | -$15 | -$15 |
| % Margin | -139.5% | -313.9% | -207.3% | -216.2% |
| EPS | -5.16 | -11.3 | -26.05 | -30.33 |
| % Growth | 54.3% | 56.6% | 14.1% | – |
| EPS Diluted | -5.16 | -11.3 | -26.05 | -30.33 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$7 | -$6 | -$15 | -$28 |
| % Margin | -148.6% | -128.7% | -198.8% | -408.7% |